Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland

Abstract

BackgroundPrehospital low‐titer group O whole blood (LTOWB) used for patients with life‐threatening hemorrhage is often RhD positive. The most important complication following RhD alloimmunization is hemolytic disease of the fetus and newborn (HDFN). Preceding clinical use of RhD positive LTOWB, we estimated the risk of HDFN due to LTOWB prehospital transfusion in the Finnish population.Study Design and MethodsWe collected data on prehospital transfusions in Tampere and Helsinki University Hospital areas. Using the mean of reported alloimmunization rates in trauma studies (24%) and a higher reported rate representing trauma patients of 13–50 years old (42.7%), we estimated the risk of HDFN and extrapolated it to the whole of Finland.ResultsWe estimated that in Finland, with the current prehospital transfusion rate we would see 1–3 cases of severe HDFN due to prehospital LTOWB transfusions every 10 years, and fetal death due to HDFN caused by LTOWB transfusion less than once in 100 years.DiscussionThe estimated risk of serious HDFN due to prehospital LTOWB transfusion in the Finnish population is similar to previous estimates. As Finland routinely screens expectant mothers for red blood cell antibodies and as the contemporary treatment of HDFN is very effective, we support the prehospital use of RhD positive LTOWB in all patient groups.